RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

S, Loi; S, Dushyanthen; PA, Beavis; R, Salgado; C, Denkert; P, Savas; S, Combs; DL, Rimm; JM, Giltnane; MV, Estrada; V, Sánchez; ME, Sanders; RS, Cook; MA, Pilkinton; SA, Mallal; K, Wang; VA, Miller; PJ, Stephens; R, Yelensky; FD, Doimi; H, Gómez; SV, Ryzhov; PK, Darcy; CL, Arteaga; JM, Balko

doi:10.1158/1078-0432.ccr-15-1125

Public

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Shared by NobleBlocks on Oct 29, 2015 • 12:00 AM UTC

Authors:

Loi S

Dushyanthen S

Beavis PA

Abstract

<h4>Purpose</h4>Tumor-infiltrating lymphocytes (TIL) in the residual disease (RD) of triple-negative breast cancers (TNBC) after neoadjuvant chemotherapy (NAC) are associated with improved survival, but insight into tumor cell-autonomous molecular pathways affecting these features are lacking.<h4>Ex...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!